Zhengye Biotech IPO: Underwriters Exercise Full Over-Allotment Option
Ticker: ZYBT · Form: 6-K · Filed: Jan 14, 2025 · CIK: 1975641
| Field | Detail |
|---|---|
| Company | Zhengye Biotechnology Holding Ltd (ZYBT) |
| Form Type | 6-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $4.00, $6,900,000, b |
| Sentiment | bullish |
Sentiment: bullish
Topics: ipo, over-allotment, shares
TL;DR
Zhengye Biotech IPO: Underwriters bought an extra 225k shares at $4.00, showing strong demand.
AI Summary
On January 13, 2025, Kingswood Capital Partners, LLC, acting for the underwriters, fully exercised their over-allotment option for Zhengye Biotechnology Holding Limited's initial public offering. This involved purchasing an additional 225,000 ordinary shares at the public offering price of US$4.00 per share.
Why It Matters
The full exercise of the over-allotment option indicates strong demand for Zhengye Biotechnology's shares post-IPO, potentially signaling investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine report on the exercise of an over-allotment option following an IPO, with no immediate negative financial implications.
Key Numbers
- 225,000 — Additional Shares (Purchased by underwriters due to full exercise of over-allotment option.)
- US$4.00 — Share Price (The price at which the additional shares were purchased.)
Key Players & Entities
- Kingswood Capital Partners, LLC (company) — Representative of the underwriters
- Zhengye Biotechnology Holding Limited (company) — Company whose shares were offered
- US$4.00 (dollar_amount) — Public offering price per share
- 225,000 (dollar_amount) — Number of additional shares purchased
- January 13, 2025 (date) — Date of over-allotment option exercise
FAQ
What is the total value of the shares purchased through the over-allotment option?
The total value is US$900,000, calculated by multiplying the 225,000 additional shares by the US$4.00 per share price.
Who acted as the representative for the underwriters in this transaction?
Kingswood Capital Partners, LLC acted as the representative of the underwriters.
What type of shares were purchased?
Ordinary shares of Zhengye Biotechnology Holding Limited were purchased.
What is the filing date of this report?
This report was filed on January 14, 2025.
What is the principal executive office address of Zhengye Biotechnology Holding Limited?
The principal executive office is located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China.
Filing Stats: 343 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2025-01-14 16:10:05
Key Financial Figures
- $4.00 — mpany at the public offering price of US$4.00 per share (the “Option”). T
- $6,900,000, b — of the over-allotment shares, totaled US$6,900,000, before deducting underwriting discounts a
Filing Documents
- ea0227639-6k_zhengye.htm (6-K) — 17KB
- ea022763901ex99-1_zhengye.htm (EX-99.1) — 11KB
- 0001213900-25-003416.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Zhengye Biotechnology Holding Limited Date: January 14, 2025 By: /s/ Songlin Song Name: Songlin Song Title: Chief Executive Officer 2